Clinical trial NCT02708992: Cefixime / Azithromycin pK Study
Official title: The Pharmacokinetics of Extended Duration High-Dose Cefixime Co-administered With Azithromycin for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Gonorrhoea
Keywords: Azithromycin
Cefixime
Duration
High-Dose
Neisseria gonorrhoeae
Pharmacokinetics
Susceptibility
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor class: NIH
First posted: 2016-03-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a PK study of a multi-dose oral cefixime regimen (three 800 mg doses given on a q 8-hour schedule) alone and also co administered with a single 1000 mg oral dose of azithromycin, both within a 24-hour period, in order to achieve total serum cefixime levels of mcg/mL for at least 20 hours. This will determine the tolerability of the regimen and whether there are significant changes in cefixime PK after co-administration. The primary pharmacokinetic objectives are: to determine if a cefixime dosing regimen of three 800 mg doses given alone, on a q 8-hour schedule achieves a total serum cefixime level that exceeds 2.0 mcg/mL for at least 20 hours; to determine if a cefixime dosing regimen of three 800 mg doses given on a q 8 hour schedule co-administered with a single 1000 mg of azithromycin, achieves a total serum cefixime level that exceeds 2.0 mcg/mL for at least 20 hours; and to evaluate whether a single 1000 mg dose of azithromycin alters the PK of a three dose regimen of 800

Detailed description: This is a PK study of a multi-dose oral cefixime regimen (three 800 mg doses given on a q 8-hour schedule) alone and also co administered with a single 1000 mg oral dose of azithromycin, both within a 24-hour period, in order to achieve total serum cefixime levels of mcg/mL for at least 20 hours. This will determine the tolerability of the regimen and whether there are significant changes in cefixime PK after co-administration. The primary pharmacokinetic objectives are: to determine if a cefixime dosing regimen of three 800 mg doses given alone, on a q 8-hour schedule achieves a total serum cefixime level that exceeds 2.0 mcg/mL for at least 20 hours; to determine if a cefixime dosing regimen of three 800 mg doses given on a q 8 hour schedule co-administered with a single 1000 mg of azithromycin, achieves a total serum cefixime level that exceeds 2.0 mcg/mL for at least 20 hours; and to evaluate whether a single 1000 mg dose of azithromycin alters the PK of a three dose regimen of 800 mg cefixime given on a q 8-hour schedule. The primary safety objectives are to assess the safety and tolerability of a treatment regimen that includes three doses of 800 mg cefixime; to assess the safety and tolerability of a treatment regimen that includes three doses of 800 mg cefixime co-administered with a single 1000 mg dose of azithromycin. The study will take place for 10 weeks.

Eligibility criteria: Inclusion Criteria:

1. Healthy male or female subjects between 18 and 45 years, inclusive 2. Ability to understand the consent process and procedures 3. Informed consent obtained and signed prior to initiation of any study procedures 4. Subjects agree to be available for all study visits 5. Negative breathalyzer for alcohol 6. Agreement by female subjects with reproductive potential to use an adequate method of contraception during the study and for 30 days after last study drug administration. Female subjects must agree to the use of TWO reliable methods of contraception while receiving study drug and for 30 days after last study drug administration if sexually active, which can include: condoms, spermicidal gel, diaphragm, hormonal or non-hormonal intrauterine device, surgical sterilization, oral contraceptive pill (OCP), and depot progesterone injections.

Exclusion Criteria:

1. Subjects who take any prescription medication on a regular basis (except OCPs), including but not limited to, anti-psychotics, anti-depressants, anti-epileptics, cardiac medications, and antihypertensives. 2. Subjects who take any OTC drugs or herbal remedies on a regular basis, especially those that have been associated with a risk of QT prolongation such as antiemetics (ondansetron, granisetron, dolasetron, hydroxyzine), antihistamines (terfenadine, astemizole, hydroxyzine, diphenhydramine), GI stimulants (cisapride, domperidone, metoclopramide), and homeopathic agents (cinchona, licorice extract- glycyrrhizin). 3. Hypertension with confirmed systolic blood pressure \>140 mmHg or confirmed diastolic blood pressure \> 90 mmHg, measured after 10 to 15 minutes of rest 4. Morbid obesity (BMI \>/= 35 kg/m\^2) 5. Current diagnosis of pulmonary disease 6. History or current diagnosis of diabetes 7. Autoimmune disorders, such as lupus, Wegener's, rheumatoid arthritis 8. History of malignancy except low-grade skin cancer, (i.e., basal cell carcinoma thought to be cured) 9. Known diagnosis of prolonged QT interval, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure 10. History of alcohol abuse 11. History of seizure disorder 12. History of renal disease 13. Chronic renal, hepatic, or pulmonary disease or other condition that could interfere with the absorption of the study drug or predispose to adverse GI events (e.g., surgical resection of significant proportions of the stomach or bowel, gastric bypass, gastric banding, irritable bowel syndrome, inflammatory bowel disease) 14. Positive serology results for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies 15. Subjects who have taken any prescription drugs in the previous 14 days or within five half-lives before dosing 16. Ingestion of OTC medications or herbal supplements within seven days of dosing 17. Positive urine drug screen for marijuana, cocaine, amphetamines, opiates, phencyclidine, barbiturates, or benzodiazepines 18. History of allergic reaction or intolerance to cephalosporins 19. History of allergic reaction to penicillin (all stages) 20. History of allergic reaction to azithromycin, erythromycin, or any macrolide or ketolide antibiotic 21. History of jaundice or hepatic dysfunction associated with prior use of azithromycin 22. Males with a QTcF \> 430ms or Females with a QTcF \>450ms (Fridericia's correction) on screening 23. Positive pregnancy test; pregnant or nursing women 24. Screening laboratory tests \> Grade 1 as defined by Appendix B 25. Any specific condition that, in the judgment of the Investigator, precludes participation because it could affect subject safety.

Primary outcomes:
measure: AUC from 0 to infinity [AUC0-infinity]
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Averaged composite plasma cefixime levels will be used to generate PK curves of cefixime levels versus time
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Elimination half-life (t1/2)
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Elimination rate (lambda z)
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Individual plasma cefixime levels will be used to generate PK curves of cefixime levels versus time
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Peak cefixime level (Cmax)
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Safety blood test results
timeFrame: Day: -28,-1, 2, 3, 9, 11, 12, 17 and at early termination
measure: Safety urinanalysis results
timeFrame: Day: -28, -1, 2, 3, 9, 11, 12, 17 and at early termination
measure: Subject reported AEs
timeFrame: Day: 1, 2, 3, 9, 10, 11, 12, 17 and at early termination
measure: Subject reported serious adverse events (SAEs)
timeFrame: Day: 1, 2, 3, 9, 10, 11, 12, 17 and at early termination
measure: Targeted clinical evaluations
timeFrame: Day: -1,1, 2, 3, 9, 10, 11, 12, 17 and at early termination
measure: Time that cefixime levels exceed four times the MIC of 0.5 mcg/mL (i.e., a plasma level of 2.0 mcg/mL)
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Time to peak drug level (Tmax)
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Total area under the curve (AUC from 0 hours to the time of next dosing [AUC0-t])
timeFrame: Day 1,2,3,10,11,12 and at early termination
measure: Total plasma concentrations of cefixime
timeFrame: Day 1,2,3,10,11,12 and at early termination
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
state: North Carolina
Study officials:
References: